Study on retreatment of CHC patients with initial treatment failure.
- Author:
Lu ZHANG
1
;
Ge SHEN
;
Yan-Li ZHANG
;
Guo-Hua QIU
;
Yao LU
;
Hui ZHAO
;
Min YANG
;
Ming-Hui LI
;
Yao XIE
;
Jun CHENG
;
Dao-Zhen XU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Aged; Antiviral Agents; therapeutic use; Female; Hepacivirus; drug effects; genetics; isolation & purification; physiology; Hepatitis C, Chronic; drug therapy; virology; Humans; Interferon-alpha; therapeutic use; Male; Middle Aged; Polyethylene Glycols; therapeutic use; Recombinant Proteins; therapeutic use; Retreatment; Ribavirin; therapeutic use; Treatment Failure; Viral Load; drug effects; Young Adult
- From: Chinese Journal of Experimental and Clinical Virology 2012;26(4):304-306
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the retreatment of CHC patients with initial treatment failure and how to achieve SVR.
METHODS54 patients who had experienced treatment failure were enrolled and retreated with standard treatment of pegylated interferon and ribavirin or intensive treatment, respectively. Their SVR rates were statistically compared, to decide two therapies' application.
RESULTS54 patients had been retreated, and total SVR rate was up to 75.92%, with 88.46% in relapsed patients and 64.29% in non-responders. After retreatment with pegylated interferon and ribavirin, SVR rate was 95.45% in patients with prior interferon monotherapy, and 64.71% in patients with prior interferon and ribavirin, and 60% in patients with prior pegylated interferon alpha-2a monotherapy. SVR rate of relapsed patients was significantly higher than that of non-responders.
CONCLUSIONSIn CHC patients with treatment failure, SVR rate of retreatment with standard treatment or intensive treatment still can be up to 60%-90%. Retreatment with standard therapy can be applied to patients who had received interferon monotherapy or interferon plus ribavirin. Three types of patients who need intensive retreatment were as following: patients nonresponsive to interferon plus ribavirin or pegylated interferon alpha-2a monotherapy, and patients with treatment failure who had received prior standard treatment.
